Y5 - Ovarian tumour (benign and malignant) Flashcards

1
Q

what provides a definitive diagnosis of ovarian cancer

A

surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

def of an epithelial ovarian cancer

A

a malignant transformation of the ovarian capsule epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are different sub-types of ovarian cancer

A

epithelial, germ cell, and sex-cord tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

aetiology

A

genetic causes implicated

  • BRCA1/2
  • HNPCC mutations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

where do ovarian cancers often originate

A

the fallopian tubes at the distal fimbral portion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

does epithelial ovarian cancer invade organ space

A

normally no, usually attaches to the surface of organs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

epi

A

most lethal gynaecological cancer

elderly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

is ovarian cancer more common in white women or black women

A

white women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

RFs

A

increasing age
FHx of ovarian/breast cancer
never used OCP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what does OCP protect against

A

ovarian cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

signs and symptoms

A
RFs
pelvic mass
-adnexal mass
GI symptoms > 3 months
-bloading
-nausea
-dyspepsia
-urinary incontinence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

features of BRCA1 mutation

A

found on chr 17q

autosomal dominant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the increased risk of ovarian cancer with a BRCA1 mutation

A

35% increased lifetime risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

features of BRCA2 mutation

A

found on chr 13q

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the increased risk of ovarian cancer with a BRCA2 mutation

A

30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

first line investigation

A

pelvic ultrasound

  • solid mass
  • high blood flow (doppler)
17
Q

what cancer antigen marker is raised in ovarian cancer

A

CA 125

18
Q

what is the definitive test for ovarian cancer

A

surgery and histopathology

19
Q

why do patients commonly present at late stages of ovarian cancer

A

due to vague and non-specific symptoms

20
Q

what are the four stages of ovarian cancer

A

Stage 1 - confined to ovaries
Stage 2 - involves pelvic extension or primary peritoneal cancer
Stage 3 - spread to the peritoneum outside the pelvis or metastasis to retroperitoneal lymph ndoes
stage 4 - distant metastasis

21
Q

what are the cornerstones of ovarian cancer treatment

A

surgery and chemotherapy

22
Q

what is standard therapy for ovarian cancer

A

maximal surgical debulking and chemotherapy

23
Q

management for stage I ovarian cancer

A

surgery

24
Q

management for stages II-IV ovarian cancer with optimal debulking

A

IV and intraperitoneal chemotherapy with paclitaxel and cisplatin

25
Q

management for stages II-IV ovarian cancer with sub-optimal debulking

A

IV chemotherapy with carboplatin and paclitaxel OR docetaxel

26
Q

management for platinum sensitive recurrent disease

A

carboplatin and paclitacel or doxorubicin liposomal

27
Q

management for platinum resistant recurrent disease

A

doxorubicin liposomal

28
Q

prevention for ovarian cancer

A

OCP

29
Q

complications

A

intraperitoneal therapy failure
plantar-palmar erythrodysaesthesia
alopecia

30
Q

what causes plantar-palmar erythrodysaesthesia

A

doxorubicin liposomal

31
Q

what is plantar-palmar erythrodysaesthesia

A

paraesthesia with painful redness of palms and soles

32
Q

prognosis

A

majority of patients have remission after first line therapy

33
Q

what is the most important prognostic factor for relapse

A

treatment-free interval or time from completion of first line therapy to reoccurrance

34
Q

what has worse prognosis, platinum sensitive or platinum resistant ovarian cancer

A

platinum resistant